Klinikum Wels-Grieskirchen Report issue

Academic/Hospital Phase 1 Phase 2

Organization Overview

First Clinical Trial
2010
NCT01368757
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Dr. Vera Trommet | Klinikum Wels-Grieskirchen | Klinikum Wels-Grieskirchen GmbH | Klinikum Wels-Grieskirchen GmbH, 4. Interne

Active Ingredients

Drugs in Phase 2 Trials (1)

lenalidomide (revlimid) (1 trial)

Drugs in Phase 1 Trials (1)

interferon alpha-2b (Intron-A) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Leukemia (Phase 2)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 1)

Leukemia, Myeloid (Phase 1)

Leukemia, Myeloid, Chronic-Phase (Phase 1)

Leukemia, Myelomonocytic, Acute (Phase 2)

Leukemia, Myelomonocytic, Chronic (Phase 2)

Leukemia, Myelomonocytic, Juvenile (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2